South Africa suspends inoculations with AstraZeneca's coronavirus disease 2019 (COVID-19) vaccine; mask mandates linked with reduction in COVID-19 hospitalizations; VBID's monthly office hours to be held this week.
After preliminary data from a small study suggested that the AstraZeneca coronavirus disease 2019 (COVID-19) vaccine provided minimal protection against mild to moderate disease caused by the B.1.351 variant in South Africa, the country suspended plans to vaccinate its health care workers. Reported by The Associated Press, South Africa received its first 1 million doses of the AstraZeneca vaccine last week, but will now transition to vaccinating its frontline workers with the vaccine manufactured by Johnson & Johnson. More than 90% of new cases in South Africa have the more contagious variant.
According to a study published last Friday by the CDC, states and counties that implemented mask mandates exhibited a significant decline in hospitalizations due to COVID-19 symptoms in the weeks after the requirements became active. Reported by The Hill, hospitalization growth rates dropped slightly in the first 3 weeks after the mandates took effect, and after 3 weeks, they declined by nearly 5%, dropping most significantly among Americans aged 18 to 64. They declined the least for those over the age of 65.
This week, the Value-Based Insurance Design (VBID) Model team will host its monthly office hours, in which presenters will provide technical and operational support on the VBID Model, as well as the Hospice Benefit Component and the application cycle for eligible Medicare Advantage (MA) organizations seeking to participate in the MA VBID Model in 2022. Set for Thursday, February 11, at 4:00 pm EST, the session will answer questions received in advance to the VBID mailbox and attendees will be able to ask additional questions.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More